FDA Clears First Oral GLP-1 Obesity Therapy: Wegovy Pill Gets Green Light

Turning injections into tablets echoes 1987’s switch from IV to oral zidovudine for HIV—scaling access by stripping away needles and cold-chain logistics. It fits a century-long pattern: pharmaceutical fixes racing to outpace lifestyle-driven metabolic disease that exploded after 1970’s cheap processed calories. Like 1999’s debut of orlistat (eventually marginalised by modest efficacy and side-effects), oral semaglutide could either mainstream anti-obesity therapy or repeat past boom-bust cycles if long-term safety, affordability, or insurance coverage falter. The move also accelerates structural pressure on food manufacturers, echoing how widespread statin use in the 1990s reshaped the cardiac-risk narrative and product reformulation. Whether this pill marks a genuine inflection in obesity rates or just medicalises another chronic condition will be judged decades hence—when historians weigh pharmacological appetite suppression against systemic changes in food systems, urban design and inequality.